体重与急性缺血性卒中静脉阿替普酶疗效的关系:ENCHANTED试验
ENCHANTED试验的事后分析纳入3206例(剂量比较)和4458例(全队列)急性缺血性卒中患者,评估体重是否影响低剂量与标准剂量阿替普酶的疗效。结果显示体重未显著改变两种剂量对功能恢复、死亡或症状性颅内出血的比较效果;全队列中体重与90天改良Rankin量表评分呈非线性关系,拐点约74 kg,体重<74 kg者不良功能结局和死亡风险更高,但症状性颅内出血未增加。
要点
- 体重与90天功能结局呈非线性关系,拐点约74 kg。
- 体重<74 kg者不良功能结局和死亡风险更高,但症状性颅内出血未增加。
核心结论
- 体重未显著改变低剂量与标准剂量静脉阿替普酶对急性缺血性卒中患者功能恢复、死亡或症状性颅内出血的比较效果。
- 低体重预测溶栓后不良功能结局和死亡,但不增加症状性颅内出血风险。
研究设计与样本
- ENCHANTED试验的事后分析,该试验为国际部分析因随机对照试验,比较低剂量(0.6 mg/kg)与标准剂量(0.9 mg/kg)静脉阿替普酶及强化降压与指南推荐降压治疗。
- 剂量比较臂纳入3206例患者(平均年龄66.6岁,女性37.9%),全队列纳入4458例患者(平均年龄66.7岁,女性37.8%)。
- 主要结局为90天不良功能结局,定义为改良Rankin量表评分2-6分(对比0-1分)。
- 采用逻辑回归模型分析体重与结局的关联,并使用限制性立方样条评估治疗效应与体重的关联形状。
主要发现
- 在3206例剂量比较臂中,体重未显著改变低剂量与标准剂量阿替普酶对功能恢复的交互作用(P交互=0.60)。
- 体重未显著改变两种剂量对死亡的交互作用(P交互=0.56)或对症状性颅内出血的交互作用(P交互=0.46)。
- 在全队列4458例中,连续体重与90天改良Rankin量表评分呈非线性关系,拐点约74 kg。
- 体重<74 kg的患者不良功能结局的比值比为1.41(95%CI 1.06-1.87;P=0.017),死亡的比值比为1.65(95%CI 1.04-2.61;P=0.03)。
- 体重<74 kg未增加症状性颅内出血的风险。
关键数值与推荐
- 低剂量阿替普酶为0.6 mg/kg,标准剂量为0.9 mg/kg。
- 强化降压目标为收缩压130-140 mm Hg,指南推荐降压目标为收缩压<180 mm Hg。
- 不良功能结局定义为90天改良Rankin量表评分2-6分。
- 体重拐点约74 kg;体重<74 kg者不良功能结局OR 1.41(95%CI 1.06-1.87;P=0.017),死亡OR 1.65(95%CI 1.04-2.61;P=0.03)。
临床怎么用
- 对于急性缺血性卒中静脉溶栓患者,体重不应作为选择低剂量或标准剂量阿替普酶的依据。
- 低体重(<74 kg)患者溶栓后功能结局和死亡风险较高,应加强监测和综合管理。
- 低体重患者未显示症状性颅内出血风险增加,不应仅因低体重而限制溶栓治疗。
局限性
- 本研究为ENCHANTED试验的事后分析,结果需谨慎解读。
- 体重与结局的关联可能受未测量混杂因素影响。
- 研究结论主要基于ENCHANTED试验人群,外推至其他人群需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic significance of body weight in patients receiving thrombolysis for acute ischemic stroke remains uncertain. This study aimed to determine whether body weight modifies the comparative effects of low- versus standard-dose intravenous alteplase and to evaluate the associations of body weight and clinical outcomes in patients with acute ischemic stroke. METHODS: A post hoc analysis of the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study), an international partial-factorial randomized controlled trial comparing low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase and intensive (target systolic blood pressure 130-140 mm Hg) versus guideline-recommended (target systolic blood pressure <180 mm Hg) treatment. The primary outcome was poor functional outcome at 90 days, defined as a modified Rankin Scale score of 2 to 6 (versus 0-1). For the first objective, the exposure was defined as alteplase dose and body weight, whereas for the second objective, body weight alone was considered as the exposure. Logistic regression models were performed to analyze the association between body weight and outcome. The association shape between treatment effect and body weight was evaluated using restricted cubic splines. RESULTS: Among 3206 patients (mean age, 66.6 years; female 37.9%) in the alteplase-dose arm, body weight did not significantly modify the comparative effects of low- versus standard-dose alteplase on functional recovery (Pinteraction=0.60), death (Pinteraction=0.56), or symptomatic intracerebral hemorrhage (Pinteraction=0.46). In the full cohort of 4458 patients (mean age 66.7 years; female 37.8%), a nonlinear relationship was observed between continuous body weight and 90-day modified Rankin Scale score, with an inflection point at ≈74 kg. Patients weighing <74 kg had a significantly higher likelihood of poor functional outcome (odds ratio, 1.41 [95% CI, 1.06-1.87]; P=0.017) and death (1.65 [95% CI, 1.04-2.61]; 0.03), but not an increase in symptomatic intracerebral hemorrhage. CONCLUSIONS: There was no evidence of effect modification by body weight on the effectiveness of low- versus standard-dose intravenous alteplase in patients with acute ischemic stroke. Low body weight predicts a poor outcome but not an increased risk of symptomatic intracerebral hemorrhage after thrombolysis treatment for acute ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01422616. URL: https://anzctr.org.au; Unique identifier: ACTRN12611000236998.
引用
- Ge Y, Gao Y, Chen X, et al. Body Weight in Relation to the Effectiveness of Intravenous Alteplase in Acute Ischemic Stroke: The ENCHANTED Trial. Stroke. 2026. PMID: 42644244. doi:10.1161/STROKEAHA.125.053569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。